Trial Profile
A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs FOR-46 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Fortis Therapeutics
- 26 Feb 2024 According to a FibroGen media release, additional data from this Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in 1Q 2024.
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 29 Apr 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.